| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 18 | 2023 | 1059 | 2.820 |
Why?
|
| Neoplastic Stem Cells | 10 | 2021 | 142 | 1.530 |
Why?
|
| Neoplasms | 12 | 2023 | 2809 | 1.480 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2022 | 1079 | 1.460 |
Why?
|
| Medical Oncology | 4 | 2023 | 350 | 1.420 |
Why?
|
| Artificial Intelligence | 6 | 2023 | 261 | 1.340 |
Why?
|
| Salivary Gland Neoplasms | 6 | 2021 | 65 | 1.320 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 124 | 1.300 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 242 | 1.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 5 | 2018 | 28 | 1.160 |
Why?
|
| Hematology | 1 | 2023 | 29 | 0.940 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.930 |
Why?
|
| Biomarkers, Tumor | 6 | 2022 | 1450 | 0.920 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1063 | 0.910 |
Why?
|
| Lenses | 1 | 2022 | 4 | 0.890 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 582 | 0.890 |
Why?
|
| Medicine | 1 | 2022 | 87 | 0.850 |
Why?
|
| Carcinoma | 2 | 2022 | 431 | 0.840 |
Why?
|
| Humans | 77 | 2023 | 84431 | 0.830 |
Why?
|
| Lens, Crystalline | 1 | 2022 | 68 | 0.830 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 62 | 0.800 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.800 |
Why?
|
| Specimen Handling | 1 | 2021 | 96 | 0.790 |
Why?
|
| Academies and Institutes | 1 | 2020 | 30 | 0.780 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 35 | 0.780 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 17 | 0.780 |
Why?
|
| Microsatellite Instability | 4 | 2021 | 40 | 0.780 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 723 | 0.760 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 1196 | 0.750 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 8 | 0.740 |
Why?
|
| ras Proteins | 1 | 2020 | 128 | 0.740 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 136 | 0.730 |
Why?
|
| Mouth Neoplasms | 4 | 2023 | 196 | 0.730 |
Why?
|
| Cyclin D1 | 1 | 2019 | 83 | 0.720 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 290 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 2401 | 0.720 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2235 | 0.710 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 1155 | 0.710 |
Why?
|
| Leadership | 1 | 2020 | 130 | 0.700 |
Why?
|
| Machine Learning | 6 | 2023 | 215 | 0.670 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 133 | 0.660 |
Why?
|
| Cell Proliferation | 8 | 2021 | 1566 | 0.650 |
Why?
|
| Neoplasm Staging | 7 | 2022 | 1929 | 0.640 |
Why?
|
| Carcinoma, Mucoepidermoid | 4 | 2019 | 17 | 0.630 |
Why?
|
| Transcriptome | 2 | 2021 | 559 | 0.620 |
Why?
|
| Precision Medicine | 1 | 2021 | 383 | 0.600 |
Why?
|
| Patient Selection | 1 | 2020 | 684 | 0.590 |
Why?
|
| Mutation | 6 | 2021 | 3904 | 0.580 |
Why?
|
| Papillomaviridae | 3 | 2022 | 156 | 0.580 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 404 | 0.570 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 2845 | 0.570 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 1195 | 0.570 |
Why?
|
| Cell Line, Tumor | 16 | 2021 | 2395 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 455 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2018 | 29 | 0.460 |
Why?
|
| Interleukin-6 | 3 | 2020 | 244 | 0.440 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 2329 | 0.440 |
Why?
|
| Tumor Burden | 4 | 2022 | 280 | 0.400 |
Why?
|
| Female | 33 | 2022 | 43875 | 0.400 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 261 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2022 | 1262 | 0.390 |
Why?
|
| Prognosis | 7 | 2023 | 3626 | 0.380 |
Why?
|
| Immunotherapy | 8 | 2023 | 602 | 0.370 |
Why?
|
| Mice | 21 | 2021 | 11056 | 0.360 |
Why?
|
| Tumor Microenvironment | 6 | 2023 | 386 | 0.350 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 346 | 0.340 |
Why?
|
| Models, Biological | 3 | 2022 | 1731 | 0.330 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 142 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 288 | 0.320 |
Why?
|
| Mice, SCID | 6 | 2018 | 251 | 0.320 |
Why?
|
| Cisplatin | 6 | 2022 | 603 | 0.310 |
Why?
|
| Middle Aged | 19 | 2022 | 24746 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2017 | 13 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2017 | 28 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 370 | 0.300 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 243 | 0.300 |
Why?
|
| Animals | 25 | 2022 | 26192 | 0.300 |
Why?
|
| Algorithms | 4 | 2023 | 1812 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 4 | 2022 | 210 | 0.280 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1362 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 903 | 0.260 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 532 | 0.260 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 17 | 0.260 |
Why?
|
| Paclitaxel | 4 | 2022 | 459 | 0.250 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 427 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 855 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 918 | 0.240 |
Why?
|
| Male | 20 | 2022 | 40422 | 0.240 |
Why?
|
| Xerostomia | 1 | 2023 | 10 | 0.240 |
Why?
|
| Mouth Diseases | 1 | 2023 | 15 | 0.230 |
Why?
|
| Oral Medicine | 1 | 2023 | 4 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2021 | 2717 | 0.230 |
Why?
|
| Piperazines | 3 | 2019 | 269 | 0.230 |
Why?
|
| Drug Design | 1 | 2023 | 123 | 0.230 |
Why?
|
| Re-Irradiation | 1 | 2022 | 16 | 0.220 |
Why?
|
| Pyridines | 3 | 2019 | 305 | 0.220 |
Why?
|
| Uncertainty | 1 | 2022 | 71 | 0.220 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 4 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 123 | 0.210 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 31 | 0.210 |
Why?
|
| Cloud Computing | 1 | 2021 | 7 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 194 | 0.210 |
Why?
|
| Data Accuracy | 1 | 2021 | 28 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 69 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 47 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1054 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
| DNA, Viral | 1 | 2022 | 263 | 0.200 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 36 | 0.200 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.200 |
Why?
|
| Neck Dissection | 1 | 2021 | 67 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 62 | 0.200 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 9 | 0.200 |
Why?
|
| Acetophenones | 1 | 2020 | 27 | 0.200 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 165 | 0.200 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 271 | 0.190 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 21 | 0.190 |
Why?
|
| Recombinational DNA Repair | 1 | 2020 | 9 | 0.190 |
Why?
|
| 4-1BB Ligand | 1 | 2020 | 1 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 18 | 0.190 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2020 | 15 | 0.190 |
Why?
|
| Aged | 11 | 2021 | 18157 | 0.190 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 87 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 588 | 0.190 |
Why?
|
| Actomyosin | 1 | 2020 | 43 | 0.190 |
Why?
|
| User-Computer Interface | 1 | 2021 | 185 | 0.190 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 91 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 69 | 0.190 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 526 | 0.180 |
Why?
|
| Naphthalenes | 1 | 2019 | 45 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 181 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8152 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 447 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2022 | 7829 | 0.180 |
Why?
|
| Mitosis | 2 | 2017 | 149 | 0.180 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 459 | 0.180 |
Why?
|
| Cytoskeleton | 1 | 2020 | 186 | 0.180 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 182 | 0.170 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 28 | 0.170 |
Why?
|
| Quinolines | 1 | 2019 | 94 | 0.170 |
Why?
|
| Olfactory Mucosa | 1 | 2018 | 33 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 50 | 0.170 |
Why?
|
| Point Mutation | 1 | 2019 | 246 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 135 | 0.170 |
Why?
|
| Cell Adhesion | 2 | 2020 | 416 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2018 | 55 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 169 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 102 | 0.170 |
Why?
|
| Indoles | 1 | 2020 | 316 | 0.170 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 721 | 0.160 |
Why?
|
| Students, Medical | 1 | 2023 | 383 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 128 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2023 | 4091 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.160 |
Why?
|
| Computational Biology | 1 | 2021 | 527 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 375 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 153 | 0.160 |
Why?
|
| Capecitabine | 1 | 2017 | 87 | 0.150 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 14 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 459 | 0.150 |
Why?
|
| Logistic Models | 1 | 2020 | 1168 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2020 | 534 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2018 | 458 | 0.150 |
Why?
|
| Gossypol | 1 | 2016 | 6 | 0.150 |
Why?
|
| Signal Transduction | 6 | 2021 | 3198 | 0.150 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 378 | 0.150 |
Why?
|
| Trans-Activators | 1 | 2019 | 428 | 0.150 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 48 | 0.150 |
Why?
|
| Time Factors | 4 | 2020 | 5179 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2017 | 231 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 658 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2016 | 102 | 0.140 |
Why?
|
| Retinal Dehydrogenase | 1 | 2015 | 6 | 0.140 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2208 | 0.140 |
Why?
|
| Taxoids | 1 | 2016 | 129 | 0.140 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 35 | 0.140 |
Why?
|
| Biostatistics | 1 | 2015 | 20 | 0.140 |
Why?
|
| Cell Separation | 1 | 2016 | 195 | 0.140 |
Why?
|
| Aniline Compounds | 1 | 2015 | 49 | 0.140 |
Why?
|
| Risk Factors | 3 | 2021 | 5312 | 0.130 |
Why?
|
| Cell Division | 1 | 2016 | 696 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2015 | 234 | 0.130 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 304 | 0.130 |
Why?
|
| United States | 3 | 2022 | 6473 | 0.130 |
Why?
|
| Isoenzymes | 1 | 2015 | 270 | 0.130 |
Why?
|
| Microbiota | 1 | 2020 | 367 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2021 | 714 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 755 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 694 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1041 | 0.120 |
Why?
|
| Drug Synergism | 3 | 2020 | 302 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2021 | 2230 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 424 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 393 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 296 | 0.120 |
Why?
|
| Adult | 10 | 2022 | 25260 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1204 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 16 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2020 | 787 | 0.100 |
Why?
|
| Carboplatin | 2 | 2022 | 287 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 126 | 0.100 |
Why?
|
| Apoptosis | 4 | 2018 | 1669 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 53 | 0.090 |
Why?
|
| Methylmercury Compounds | 1 | 2009 | 3 | 0.090 |
Why?
|
| Milk, Human | 1 | 2009 | 43 | 0.090 |
Why?
|
| Hair | 1 | 2009 | 56 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 480 | 0.090 |
Why?
|
| Intelligence | 1 | 2009 | 71 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2011 | 368 | 0.080 |
Why?
|
| Phenotype | 3 | 2021 | 2346 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6456 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2022 | 475 | 0.080 |
Why?
|
| Biomarkers | 2 | 2023 | 1668 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 917 | 0.070 |
Why?
|
| Cytokines | 2 | 2021 | 759 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2020 | 410 | 0.070 |
Why?
|
| Cell Survival | 2 | 2018 | 967 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 856 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1955 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1646 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2018 | 502 | 0.070 |
Why?
|
| Quality of Life | 2 | 2023 | 1507 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2660 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2017 | 254 | 0.060 |
Why?
|
| European Union | 1 | 2023 | 8 | 0.060 |
Why?
|
| Pathology, Oral | 1 | 2023 | 5 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2022 | 37 | 0.060 |
Why?
|
| Adolescent | 3 | 2022 | 8828 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 288 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2023 | 102 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 131 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 140 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 123 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 135 | 0.050 |
Why?
|
| Switzerland | 1 | 2021 | 17 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 30 | 0.050 |
Why?
|
| Histological Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 271 | 0.050 |
Why?
|
| Germany | 1 | 2021 | 72 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 257 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 48 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 22 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 163 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 307 | 0.050 |
Why?
|
| Shoulder | 1 | 2021 | 39 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 79 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 147 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2020 | 6 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 10 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 2 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 555 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.050 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 19 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 23 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2020 | 30 | 0.050 |
Why?
|
| Oncogenic Viruses | 1 | 2020 | 4 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2020 | 149 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 16 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 89 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 307 | 0.050 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 22 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 74 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 164 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 97 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 18 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 270 | 0.050 |
Why?
|
| Gastritis | 1 | 2020 | 29 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 543 | 0.050 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 34 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.050 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 36 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 742 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2020 | 81 | 0.050 |
Why?
|
| Rad51 Recombinase | 1 | 2020 | 80 | 0.050 |
Why?
|
| Benchmarking | 1 | 2020 | 78 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2019 | 131 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 147 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 221 | 0.040 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2018 | 11 | 0.040 |
Why?
|
| Symbiosis | 1 | 2020 | 116 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2020 | 151 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2018 | 19 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 190 | 0.040 |
Why?
|
| Probiotics | 1 | 2020 | 81 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 72 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 5861 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 120 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 67 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 97 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 290 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 348 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2018 | 91 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 259 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 190 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 150 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 746 | 0.040 |
Why?
|
| Estrogens | 1 | 2018 | 196 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 227 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1041 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 19 | 0.040 |
Why?
|
| Actins | 1 | 2020 | 441 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 266 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2020 | 481 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 684 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 9 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 213 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1519 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 704 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 18 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1161 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 457 | 0.040 |
Why?
|
| Breast | 1 | 2018 | 286 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 749 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 1135 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 108 | 0.040 |
Why?
|
| Spiro Compounds | 1 | 2016 | 25 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 124 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2017 | 64 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 1535 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2016 | 64 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 539 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1787 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 114 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 792 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 114 | 0.040 |
Why?
|
| Bacteria | 1 | 2020 | 436 | 0.040 |
Why?
|
| G1 Phase | 1 | 2016 | 63 | 0.040 |
Why?
|
| CD24 Antigen | 1 | 2015 | 5 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 162 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 236 | 0.040 |
Why?
|
| Heterografts | 1 | 2016 | 99 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Neprilysin | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1547 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1181 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1756 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2788 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 398 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 183 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 103 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 74 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 1083 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 332 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 632 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Publishing | 1 | 2015 | 88 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 361 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1747 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3050 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 420 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1202 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 437 | 0.030 |
Why?
|
| Child | 2 | 2019 | 6763 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 673 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 167 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 309 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 1064 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1852 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 425 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 821 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1559 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1094 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1416 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1593 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2011 | 9 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1366 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2249 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 363 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 313 | 0.020 |
Why?
|
| Seychelles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Mercury | 1 | 2009 | 8 | 0.020 |
Why?
|
| Seafood | 1 | 2009 | 10 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2009 | 56 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1685 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 985 | 0.020 |
Why?
|
| Aging | 1 | 2009 | 672 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 3000 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 3577 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2161 | 0.010 |
Why?
|